At a Glance
- Company: Boehringer Ingelheim
- Location: Ingelheim, Germany
- Headline figures: Enrolled 5 patients; terminated post Feb 3 readout
- Focus area: Inhaled lentiviral gene therapy BI 3720931 for CF
- Next steps: Program discontinued; no impact on other therapies
What happened?
Boehringer Ingelheim terminated the phase 1/2 Lenticlair 1 trial evaluating BI 3720931, an inhaled lentiviral vector gene therapy for cystic fibrosis (CF), after reviewing data. The study, launched late 2024, enrolled only five patients and failed to generate clinical evidence supporting advancement. Termination followed the primary readout on 3 February 2026.
Why does it matter?
CF gene therapies aim to deliver functional CFTR genes to lung cells, potentially benefiting patients ineligible for modulators like those from Vertex. This setback highlights delivery and efficacy challenges in inhaled approaches for this lung-damaging genetic disease, amid a field with recent mRNA and other disappointments. Boehringer’s move underscores rigorous data scrutiny in early development.
Who’s behind it?
Boehringer Ingelheim, a German family-owned pharma, developed BI 3720931 in partnership with the UK Respiratory Gene Therapy Consortium and Oxford BioMedica. The spokesperson confirmed the decision, noting the therapy’s safety met expectations for an inhaled genetic treatment.
How was it achieved?
Lenticlair 1 (phase 1 open-label dose escalation; phase 2 double-blind placebo-controlled expansion) assessed safety and FEV1 change from baseline at week 8 in CF patients. Despite a safety profile aligning with inhaled gene therapy norms, efficacy data did not warrant progression. Only five patients participated before termination.
What’s next?
The BI 3720931 program is fully discontinued, with no effects on Boehringer’s other efforts, including phase 3 verducatib for CF-associated bronchiectasis. The company lists no other clinical gene therapies.